I bought in at the IPO, been a little disappointed to date. What I've learned overtime is that these offering are peanuts compared to what can be made if a company makes progress on their pipeline. KBIO has a tiny market cap, so if progress is made on its antibody therapeutics -- major upside is on the horizon. I'm keeping the faith, had a similar situation this year with ENTA, started off slow, but it doesn't take much to get some major upside. Good luck, if your long.